Literature DB >> 6344987

Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen.

P Giacomini, A K Ng, R R Kantor, P G Natali, S Ferrone.   

Abstract

Using monoclonal antibodies to distinct determinants of a human high-molecular weight melanoma-associated antigen (HMW-MAA), a double determinant immunoassay has been developed. The assay is specific and reproducible. Its sensitivity is influenced by the incubation time of antibodies with antigen sources and the combination of antibodies, as well as by the pH of the buffer and the incubation time used to coat plates with antibodies. Testing with the double determinant immunoassay of Nonidet P-40 extracts of human cell lines and of surgically removed normal and malignant tissues has confirmed the restricted tissue distribution of the HMW-MAA. In addition, significant differences have been found in the level of HMW-MAA in melanoma cell lines, as well as in melanoma lesions removed from different patients and from different sites of a given patient. The amount of HMW-MAA shed by various melanoma cell lines does not correlate with their cell surface expression and with their level in Nonidet P-40 extracts. Interferon and hyperthermia increase the shedding of the HMW-MAA by melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6344987

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Characterization and mechanistic studies of a novel melanoma-targeting construct containing IκBa for specific inhibition of nuclear factor-κB activity.

Authors:  Hong Zhou; Yuying Liu; Lawrence H Cheung; Sehoon Kim; Weihe Zhang; Khalid A Mohamedali; Preetha Anand; Walter N Hittelman; Bharat B Aggarwal; Michael G Rosenblum
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

2.  Circulating melanoma-associated antigen detected by monoclonal antibody NKI/C-3.

Authors:  C Vennegoor; P Rümke
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

3.  Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms.

Authors:  Jianbo Yang; Matthew A Price; Cheryl L Neudauer; Christopher Wilson; Soldano Ferrone; Hong Xia; Joji Iida; Melanie A Simpson; James B McCarthy
Journal:  J Cell Biol       Date:  2004-06-21       Impact factor: 10.539

Review 4.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.